


Drug discovery at the Institute of Organic Chemistry and Biochemistry – past and present

Martin Fusek

Institute of Organic Chemistry and Biochemistry CAS, Czech Republic.



Abstract

The IOCB Prague was incorporated in 1953 as a part of the Czech Academy of Sciences. Already in early seventies first drugs developed by IOCB Prague scientists entered market. These drugs were commercialized through collaboration with local pharmaceutical company SPOFA and later with company Ferring. Great success of the research of prof. Antonín Holý brought antiviral drugs which were commercialized in collaboration with KU Leuven and US company Gilead Sciences. These drugs represent one of the main pillars in the treatment of HIV and HBV patients. Over last decade we have signed several license agreements with pharmaceutical companies and currently there are more than 10 projects in a preclinical development running at the IOCB Prague.



Biography

Martin Fusek has completed his PhD in 1988 in the field of biochemistry. Main topic of his research was aspartic proteinases. After spending 5 years as a postdoc at EMBL Heidelberg and at OMRF USA he worked at companies Sigma-Aldrich and Merck. From 2007 he is back at IOCB Prague having two responsibilities – deputy director for strategic development and CEO of the IOCB Tech company – the tech transfer arm of the IOCB Prague. He published over 50 scientific publications, two scientific books and several teaching books for students. He is lecturing at the UCT Prague where he received title of professor in 2012. His H index is 20.

Publication

[2nd World Congress on Chemistry, Drug Design and Development](#) | Prague, Czech Republic | July 20-21, 2020

Citation: Martin Fusek, Drug discovery at the Institute of Organic Chemistry and Biochemistry – past and present, Drug Design 2020, 2nd World Congress on Chemistry, Drug Design and Development, Prague, Czech Republic, July 20-21, 2020, 04